Scale -


  • Revenue is 633 Rs Cr; Annual Growth is 59 %; Continuous Growth over 3 years; 5 Year CAGR is 158 %; in Bottom Quartile
  • Ebitda is 215 Rs Cr; Annual Growth is 98 %; Continuous Growth over 3 years; 5 Year CAGR is 207 %; in Bottom Quartile
  • PBT is 39.46 Rs Cr; Annual Growth is 125 %; 5 Year CAGR is 244 %; in Bottom Quartile
  • PAT is 122 Rs Cr; Annual Growth is 108 %; Continuous Growth over 3 years; 5 Year CAGR is 233 %; in Bottom Quartile
  • Quarterly Revenue is 180 Rs Cr; Continuous Growth over 3 Quarters; in Bottom Quartile

Profitability -


  • PBDIT Margin is 34.04 %; Annual Growth is 24 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 19 %
  • PAT Margin is 19.21 %; Annual Growth is 31 %; 5 Year CAGR is 29 %
  • Quarterly Ebitda Margin is 30 %; in Top Quartile

Return -


  • ROCE is 15.6 %; Annual Growth is 67 %; Continuous Growth over 3 years; 5 Year CAGR is 46 %
  • ROA is 7.19 %; Annual Growth is 51 %; 5 Year CAGR is 44 %
  • ROE is 12.35 %; Annual Growth is 66 %; 5 Year CAGR is 46 %
  • Asset Turnover is 45 %; in Bottom Quartile

Efficiency -


  • Operating cash flow is 62.05 Rs Cr; Annual Growth is 235 %; in Bottom Quartile
  • Inventory Turnover Ratio is 8.67; in Top Quartile
  • Current Ratio is 1.92; Annual Decline is -36 %
  • Quick Ratio is 1.71; Annual Decline is -38 %

Solvancy -


  • Debt/Equity is 0.35; Continuous Decline over 3 years
  • Contingent Liabilities is 30.58 Rs Cr; in Bottom Quartile; 5 Year CAGR is 38 %
  • Long term Debt is 195 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 100 %
  • Total Debt is 327 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 119 %

Quality -


  • Operating cashflow/ebitda is 29 %; Annual Growth is 168 %; Continuous Growth over 3 years; in Bottom Quartile
  • Operating cashflow/PAT is 51 %; Annual Growth is 165 %; in Bottom Quartile
  • Current Tax/PAT is 16 %; Annual Decline is -38 %; in Bottom Quartile
  • Other Expenses/Total Expenses is 19 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is 0 %; Annual Growth is 106 %
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Senores Pharma Hits Record Q2 Revenue And EBITDA, Posts 9th Straight Quarter Of Double-Digit Growth.
Senores Pharmaceuticals Plans ?43 Crore Capacity Expansion Across US and India, Adds Prefilled Syringe Line
Senores Pharma Posts Record Q2 Revenue & EBITDA
Senores Pharmaceuticals Approves ?43 Crore Expansion and Reports Q2 Profit of ?39 Crore
Senores Pharmaceuticals approves ?43 crore subsidiary expansion plan
SENORES PHARMACEUTICALS L Q2 Results FY27: PAT Falls 76.16% to Rs 7.72 Cr, Revenue Rs 35.65 Cr
Senores Pharmaceuticals Ltd announces Robust Financial & Operational Performance in Q2 and H1 FY27
Senores Pharmaceuticals SENORES Subsidiary Capacity Expansion 2027
Senores Pharmaceuticals shares fall 3% despite 22% rise in Q2 profit; revenue jumps 25%
Senores Pharmaceuticals Reappoints Swapnil Shah as Managing Director
Senores Pharmaceuticals Ltd. Estimates – NSE:SENORES
Senores Pharmaceuticals Q2FY27 Results: Earnings call moved to 4 pm
Senores Pharmaceuticals (NSE: SENORES): Share Price, Quarterly Results and FII Holding
Senores Pharmaceuticals (SENORES.NS) Climbs 2.52% to ?1290.5, Approaches Key Resistance Zone
Senores Pharmaceuticals seeks approval for MD and WTD re-appointments
Senores Pharmaceuticals SENORES Postal Ballot MD Re-appointment
Swapnil Shah gets fresh term as Senores Pharmaceuticals MD
Senores Pharmaceuticals (NSE:SENORES): What Does Its Q2 FY27 Share Capital Audit Show?
Senores Pharmaceuticals vs Nifty 50: 1Y Return +80.29% vs -10.93%
Is Senores Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers
SENORES Share Price rises 5.77%: price action, valuations